Degradable iron-base alloy support

Patent metadata

Field	Value
Publication number	US-10632232-B2
Application number	US-201515534406-A
Country	US
Kind code	B2
Filing date	Dec 2, 2015
Priority date	Dec 31, 2014
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

A degradable iron-based alloy stent comprises an iron-based alloy substrate and a degradable polymer in contact with the surface of the substrate. The weight-average molecular weight of the degradable polymer is in the range of [1, 100]*104, and the polydispersity index of the degradable polymer is in the range of (1.0, 50]. The degradable polymer is selected from a degradable polyamino acid that can generate an acidic amino acid after degradation; or a mixture of the degradable polyamino acid and a degradable polyester, or a copolymer of monomers of the two; or a mixture of the degradable polyamino acid and a degradable polymer that does not generate acidic products after degradation, or a copolymer of the monomers of the two; or a mixture of the degradable polyamino acid, the degradable polyester and the degradable polymer that does not generate acidic products after degradation, or a copolymer of monomers of the three, or a mixture of a copolymer of monomers of any two of the three with the remaining one. The numerical ranges are in conformity with mathematical knowledge, i.e. [a, b] means being greater than or equal to a and being less than or equal to b; (a, b] means being greater than a and less than or equal to b; [a, b) means being greater than or equal to a, less than b, a redundant description will not be provided for the similarity text below.

First claim

The invention claimed is:

1. A degradable iron-based stent, comprising an iron-based substrate and a degradable polymer in contact with the surface of the substrate, wherein:
the degradable polymer is a polyaspartic acid-lactic acid copolymer coating having a weight-average molecular weight of 100,000 and a polydispersity index of 3;
wherein the aspartic acid is copolymerized with lactic acid by a ratio of 1:1; and
the stent has a radial support force of above 23.3 kPa (175 mm Hg) in a radial support force test after the stent has been implanted for 3 months.

2. A degradable iron-based stent, comprising an iron-based substrate and a degradable polymer in contact with the surface of the substrate, wherein:
the iron-based substrate is an electrodeposited pure iron substrate having a wall thickness of 40 to 50 microns;
the degradable polymer is a polyglutamic acid coating having a thickness of 3 to 5 microns and is uniformly coated on the surface of the electrodeposited pure iron substrate, and the polyglutamic acid coating is coated with a polycaprolactone (PCL) rapamycin mixed coating having a thickness of 5-8 microns;
the ratio of polycaprolactone to rapamycin is 2:1;
the mass ratio of the electrodeposited pure iron substrate to the degradable polymer is 35:1;
the weight-average molecular weight of polycaprolactone is 30,000 and has a polydispersity index of 1.3;
the weight-average molecular weight of the polyglutamic acid is 80,000 and has a polydispersity index of 1.6; and
the stent has a radial support force of 60 kPa in a radial support force test after the stent has been implanted for 3 months.

3. A degradable iron-based stent, comprising an iron-based substrate and a cocoa-degradable polymer in contact with the surface of the substrate, wherein:
the iron-based substrate is a carburized iron bare stent having a wall thickness of 50 to 70 microns;
the degradable polymer is a mixed coating of polyaspartic acid and heparin having an average thickness of from 12 to 15 microns, with the polyaspartic acid and the heparin mixed by a ratio of 5:1;
the molecular weight of the polyaspartic acid is 1 million and the polyaspartic acid has a polydispersity index of 20;
the mass ratio of the iron-based substrate to degradable polymer is 30; and
the stent has a radial support force of above 23.3 kPa (175 mm Hg) in a radial support force test after the stent has been implanted for 3 months.

Assignees

• Lifetech Scient Shenzhen Co

Inventors

• Chen Liping
• Sun Hongtao
• Zhang Deyuan

Classifications

• A61L31/043

  Proteins; Polypeptides; Degradation products thereof · CPC title

• A61L31/10

  Macromolecular materials · CPC title

• A61L31/022 Primary

  Metals or alloys · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L31/041

  Mixtures of macromolecular compounds · CPC title